U.K. team spots new Alzheimer's drug targets

An initiative by scientists at King's College London - Institute of Psychiatry has identified new Alzheimer's drug targets, a finding that could greatly expand efforts to beat back the neurodegenerative disease. The scientists found by testing brain cells grown in the lab that they could block the toxic effects of amyloid plaques by stopping the DKK1-WNT signaling pathways. This cellular mechanism, they said, involves interactions between several molecules that drug developers may want to target with new treatments. The researchers add they've launched their own drug development effort to test this idea further. Details are published in the journal Molecular Psychiatry. Release